<DOC>
	<DOC>NCT02503059</DOC>
	<brief_summary>Evaluate the 3-year survival of etanercept in patients over 60 years with psoriasis in moderate / severe plaque and the reasons that led to the abandonment. Besides factors that might have had a positive or negative influence on adherence to treatment and analysis of efficacy (PASI 75) and safety will be identified. All variables were collected through retrospective review of medical records of patients dermatology unit are made.</brief_summary>
	<brief_title>Etanercept Survival in Elderly Population</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Patients with moderate / severe psoriasis (with / without psoriatic arthritis,PAs) defined by: PASI(Psoriasis Area and Severity Index)&gt; 10 and / or BSA(Body Surface Area)&gt; 10% and / or DLQI(Dermatology Life Quality Index)&gt; 10 PASI&gt; 10 and / or BSA(Body Surface Area)&gt; 10% and / or DLQI(Dermatology Life Quality Index)&gt; 10 Over 60 years of age at the start of treatment Receiving etanercept at any time Available history in the Dermatology Patients with insufficient clinical data in the medical record</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>